Nuevo horizonte en la atención farmacéutica del paciente VIH con el tratamiento antirretroviral de duración prolongada

Mercedes Gimeno-Gracia; Antonio Antela

doi:10.7399/fh.11848

Nuevo horizonte en la atención farmacéutica del paciente VIH con el tratamiento antirretroviral de duración prolongada

Mercedes Gimeno-Gracia, Antonio Antela

Resumen

Texto completo:

PDF (English) PDF

Referencias

Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-acting cabotegravir and rilpivirine for maintenace of HIV-1 suppression. N Engl J Med. 2020;382:1112-23.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124- 35.

Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, et al. Long-acting injectable cabotegravir + rilpivirina for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquir Immune Defic Syndr. 2020;85:498-506.

Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396:1994-2005.

Danchani D, Dang BN, Lucari B, Swindells S, Giordano TP. Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection. AIDS Care. 2020;14:1-9.

Murray M, Antela A, Mills A, Huang J, Jäger H, Bernal E, et al. Patient- Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks. AIDS Behav. 2020:3533-44.

Scarsi KK, Swindells S. The promise of improved adherence with long-acting antiretroviral therapy: what are the data? J Int Assoc AIDS Care. 2021;20:1-10.

Cutrell AG, Schapiro JM, Perno CF, Kuritzkes D, Quercia R, Patel P, et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS. 2021;35:1333-42.

Cantillana-Suárez MG, Robustillo-Cortés MA, Gutiérrez-Pizarraya A, Morillo-Verdugo R. Impact and acceptance of pharmacist-led interventions during HIV care in a third-level hospital in Spain using the Capacity-Motivation-Opportunity pharmaceutical care model: the IRAFE study. Eur J Hosp Pharm. 2021;24:0:1-7.

Morillo-Verdugo R, Vélez-Díaz-Pallarés M, Fernández-Pachecho García-Valdecasas M, Fernández-Espínola S, Sánchez-Rubio Ferrández J, Navarro Ruiz A. Intervención farmacéutica basada en metodología CMO para la mejora de la adherencia primaria a la medicación concomitante en pacientes con infección por VIH:Proyecto PRICMO. Farm Hosp. 2021;45:247-52.

Jackson IL, Ukwe C. Clinical outcomes of pharmaceutical care intervention in HIV positive patients with hypertension: a randomized controlled study. J Clin Pharm Ther. 2021;46:1083-94.

Gimeno-Gracia M, Sánchez-Rubio-Ferrández J, Robustillo-Cortés MA, Morillo-Verdugo R. Prevalencia de polifarmacia y complejidad farmacoterapéutica en personas mayores con VIH en España. Estudio POINT. Farm Hosp. 2020;44:127-34.

Díaz-Acedo R, Soriano-Martínez M, Gutiérrez-Pizarraya A, Fernández-González-Caballos JA, Raya-Siles M, Morillo-Verdugo R. Prevalencia y factores asociados con la presencia de criterios PIMDINAC en pacientes VIH de edad avanzada. Enferm Microbiol Clin. 2021;12:S0213-005X(20)30417-1.

Vinuesa-Hernando JM, Gimeno-Gracia M, Malo S, Sanjoaquín-Conde I, Crusells-Canales MJ, Letona-Carbajo S, et al. Potentially inappropiate prescriptions and therapeutic complexity in older HIV patients with comorbidities. Int J Clin Pharm. 2021;43:1245-50.

Contreras-Macías E, Gutiérrez-Pizarraya A, Robustillo-Cortés MA, Morillo-Verdugo R. High level of medication regimen complexity index correlate with worse quality of life in people living with HIV. Rev Esp Quimioter. 2021;34:93-9.

DOI: http://dx.doi.org/10.7399%2Ffh.11848